Cyclosporine in cardiac transplantation.
Since 1981 the authors have performed 14 orthotopic heart transplantations and one heart-lung transplantation, using cyclosporine and prednisone as immunosuppressants. Eight of the recipients had terminal congestive cardiomyopathy and six had ischemic cardiac dysfunction. The combined heart-lung transplantation was performed on a patient with a congenital ventricular septal defect with Eisenmenger's syndrome. Twelve of the patients were alive and well at follow-up 9 to 34 months (mean 17.4 months) after transplantation. One patient died of acute rejection and one of acute pancreatitis and secondary peritonitis. The third death, due to acute right ventricular failure, occurred immediately after transplantation. Rejection was diagnosed histologically on seven other occasions in four patients and was treated successfully. Infection was not a major problem. Cyclosporine -induced reversible nephrotoxicity was evident in 12 patients, 2 of whom required dialysis. Other side effects of cyclosporine seen in these patients included hypertension, gastrointestinal upset, headaches and hirsutism. This experience suggests that cyclosporine is a potent immunosuppressive agent that has greatly reduced the hazards of rejection and infection. However, the frequency of nephrotoxicity is high; careful monitoring of cyclosporine blood levels and renal function is essential.
D000293:Adolescent; D000328:Adult; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D005260:Female; D006084:Graft Rejection; D016027:Heart Transplantation; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D016040:Lung Transplantation; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D014181:Transplantation Immunology
D003524:Cyclosporins; D011241:Prednisone